Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study

Simioni, Samanta; Cavassini, Matthias; Annoni, Gian-Maria; Métral, Mélanie; Iglesias, Katia; Rimbault Abraham, Aline; Jilek, Samantha; Calmy, Alexandra; Muller, Hubertus; Fayet-Mello, Aurélie; Giacobini, Ezio; Hirschel, Bernard; Du Pasquier, Renaud A

doi:10.1212/WNL.0b013e3182815497

Scientific article

English

Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study

ContributorsSimioni, Samanta; Cavassini, Matthias; Annoni, Gian-Maria; Métral, Mélanie; Iglesias, Katia; Rimbault Abraham, Aline; Jilek, Samantha; Calmy, Alexandra

; Muller, Hubertus; Fayet-Mello, Aurélie; Giacobini, Ezio; Hirschel, Bernard; Du Pasquier, Renaud A

Published inNeurology, vol. 80, no. 6, p. 553-560

Publication date2013

Abstract

To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.

Keywords

AIDS Dementia Complex/drug therapy
Cross-Over Studies
Double-Blind Method
Executive Function/drug effects
Female
Humans
Male
Middle Aged
Neuroprotective Agents/therapeutic use
Neuropsychological Tests
Phenylcarbamates/therapeutic use
Pilot Projects

Affiliation

Research group

VIH/SIDA (930)

Citation (ISO format)

SIMIONI, Samanta et al. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study. In: Neurology, 2013, vol. 80, n° 6, p. 553–560. doi: 10.1212/WNL.0b013e3182815497

Article (Published version)

Identifiers

PID : unige:33912
DOI : 10.1212/WNL.0b013e3182815497
PMID : 23345635

ISSN of the journal0028-3878

663views

1downloads

Creation12/03/2013 3:42:00 PM

First validation12/03/2013 3:42:00 PM

Update time03/14/2023 8:56:06 PM

Status update03/14/2023 8:56:06 PM

Last indexation05/02/2024 1:47:09 PM

Archive ouverte UNIGE

Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study

To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.

Technical informations